St. John's Wort: An option for the primary care treatment of depressive patients?

European Archives of Psychiatry and Clinical Neuroscience

Volumn 253, Issue 3, 2003, Pages 140-148

  Gupta, R K ^a   Moller H J ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Depression; Hypericum; Randomised double blind controlled studies; St. John's Wort

Indexed keywords

FLUOXETINE; HYPERICUM PERFORATUM EXTRACT; IMIPRAMINE; SERTRALINE; ANTIDEPRESSANT AGENT; PLANT EXTRACT;

ABDOMINAL DISCOMFORT; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ERYTHEMA; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART MUSCLE CONDUCTION DISTURBANCE; HEART RATE; HUMAN; HYPERALGESIA; INSOMNIA; LONG QT SYNDROME; MICTURITION DISORDER; MONITORING; NAUSEA; PHOTOSENSITIVITY; PHOTOTOXICITY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TERATOGENICITY; TREATMENT OUTCOME; CHEMISTRY; CONTROLLED CLINICAL TRIAL; DRUG INTERACTION; HERBAL MEDICINE; HYPERICUM; META ANALYSIS; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; STATISTICS;

ANTIDEPRESSIVE AGENTS; DEPRESSION; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; HUMANS; HYPERICUM; MEDICINE, HERBAL; META-ANALYSIS; PLANT EXTRACTS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0041328461     PISSN: 09401334     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00406-003-0417-6     Document Type: Review

References (65)

1. Baede-van Dijk PA, van Galen E, Lekkerkerker JF (2000) Drug interactions of Hypericum perforatum (St. John's Wort) are potentially hazardous. Nederlands Tijdschrift voor Geneeskunde 144:811-812
2. Bhattacharya SK, Chakrabarti A, Chatterjee SS (1998) Activity profile of two hyperforin-containing hypericum extracts in behavioural models. Pharmacopsychiatry 31:36-43
3. Bove GM (1998) Acute neuropathy after exposure to sun in a patient treated with St. John's Wort. Lancet 352:1121-1122
4. Brantner A, Kartnig Th, Quehenberger F (1994) Vergleichende phytochemische Untersuchungen an Hypericum peforatum L und Hypericum maculatu Crantz Scient Pharm 62:261-276
5. Brockmoller J, Reum T, Bauer R, Kerb R, Hubner WD, Roots I (1997) Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry 30 (suppl 2):94-101
6. Cellarova E, Daxnerova Z, Kimakova K, Haluskova J (1994) The variability of the hypericin content in the regenerants of Hypericum perforatum. Acta Biotechnol 14:267-274
7. Chatterjee SS, Filippov V, Lishko P, Maximyuk O, Noldner M, Krishtal O (1999) Hyperforin attenuates various ionic conductance mechanisms in the isolated hippocampal neurons of rat. Life Scien 65:2395-2405
8. Conney AH (1986) Induction of microsomal cytochrome P-450 enzymes. Life Scien 39:2493-2518
9. Cott JM (1997) In vitro receptor binding and enzyme inhibition by Hypericum perforatum extract. Pharmacopsychiatry 30:108-112
10. Czekalla J, Gastpar M, Hubner WD, Jager G (1997) The effect of hypericum extract on cardiac conduction as seen in the electrocardiogram compared to that of imipramine. Pharmacopsychiatry 30 (suppl 2):86-88
11. Davidson MD, Jonathan RT, Hypericum Depression Trial Study Group (2002) Effect of Hypericum perforatum (St. John's Wort) in major depressive disorder. A randomized controlled trial. J Am Med Assoc 287:1807-1814
12. Deltito J, Beyer D (1998) The scientific, quasi-scientific and popular literature on the use of St. John's Wort in the treatment of depression. J Affect Dis 51:345-351
13. DeMott K (1998) St. John's Wort tied to serotonin syndrome. Clin Psychiatry News 26:28
14. Dimpfel W, Todorova A, Vonderheid-Guth B (1999) Pharmacodynamic properties of St. John's Wort - a single blind neurophysiological study in healthy human subjects comparing two commercial preparations. Eur J Med Res 4:303-312
15. Erdelmeier CAJ (1998) Hyperflorin, possibly the major non-nitrogenous secondary metabolite of hypericum perforatum L. Pharmacopsychiatry 31 (suppl):2-6
16. Ernst E (1995) St. John's Wort, an anti-depressant? A systematic, criteria-based review. Phytomed 2:67-71
17. Gaster B, Holroyd J (2000) St. John's Wort for depression: a systematic review. Arch Int Med 160:152-156
18. Gordon JB (1998) SSRI's and St. John's Wort: possible toxicity? Am Fam Physic 57:950-951
19. Greeson JM, Sanford B, Monti DA (2001) St. John's Wort (Hypericum perforatum): a review of the current pharmacological, toxicological, and clinical literature. Psychopharmacology 153:402-414
20. Grush LR, Nierenberg A, Keefe B, Cohen LS (1998) St. John's Wort during pregnancy. J Am Med Assoc 280:1566
21. Hadjur C, Richard MJ, Parat MO, Jardon P, Favier A (1996) Photodynamic effects of hypericin on lipid peroxidation and antioxidant status in melanoma cells. Photochemistry and Photobiol 64:375-381
22. Halama P (1991) Wirksamkeit des Johanniskraut-Extraktes LI 160 bei depressiver Verstimmung. Nervenheilk 10:250-253
23. Harrer G, Schmidt U, Kuhn U, Biller A (1999) Comparison of equivalence between the St. John's Wort extract LoHyp-57 and fluoxetine. Arzneimittel Forschung 49:289-296
24. Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M, Roots I (1999) Pharmacokinetic interaction of digoxin with an herbal extract from St. John's Wort (Hypericum perforatum). Clin Pharmacol Therap 66:3338-3345
25. Kaspar S, Dienel A (2002) Cluster analysis of symptoms during antidepressant treatment with Hypericum extract in mildly to moderately depressed out-patients. A meta-analysis of data from three randomised, placebo-controlled trials. Psychopharmacol 164:301-308
26. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 51:8-19
27. Kim HL, Streltzer J, Goebert D (1999) St. John's Wort for depression: a meta-analysis of well-defined clinical trials. J Nerv Ment Dis 187:532-538
28. Klier CM, Schäfer MR, Schmid-Siegel B, Lenz G, Mannel M (2002) St. John's Wort (Hypericum perforatum) - Is it safe during breastfeeding? Pharmacopsychiatry 5:29-30
29. Kunze H, Priebe S (1998) Assessing the quality of psychiatric hospital care: a German approach. Psychiatr Serv 49:794-796
30. Laakmann G, Schüle C, Baghai T, Kieser M (1998) St. John's Wort in mild to moderate depression: the relevance of hyperforum for the clinical efficacy. Pharmacopsychiatry 31 (suppl 1):54-59
31. Lane-Brown MM (2000) Photosensitivity associated with herbal preparations of St. John's Wort (Hypericum perforatum). Med J Austr 172:302
32. Lecrubier Y, Clerc G, Didi R, Kieser M (2002) Efficacy of St. John's Wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. Am J Psychiatry 159:1361-1366
33. Linde K, Mulrow CD (2000) St. John's Wort for depression. Cochrane Database Syst Rev CD000448
34. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart (1996) St. John's Wort for depression, an overview and meta-analysis of randomised clinical trials. Br Med J 313:253-258
35. Montgomery SA (1999) The failure of placebo-controlled studies. European Neuropsychopharmacol 9:271-276
36. Montgomery S, Hübener W, Gregoleit H (2000) Efficacy and tolerability of St. John's Wort extract compared with placebo in patients with a mild to moderate depressive disorder. Phytomed 9 (suppl II):107
37. Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Wilson TM (2000) St. John's Wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Nation Acad Scienc USA 97:7500-7502
38. Moses EL, Mallinger AG (2000) St. John's Wort: three cases of possible mania induction. J Clin Psychopharmacol 20:115-117
39. Müller WE, Rolli M, Schaeffer C (1997) Effects of Hypericum extract LI 160 in biochemical models of antidepressant activity. Pharmacopsychiatry 30 (suppl 2):102-107
40. Müller WE, Singer A, Wonneman M, Hafner U, Rolli M, Schafer C (1998) Hyperforin represents the neurotransmitter reuptake inhibiting constituent of Hypericum extract. Pharmacopsychiatry 31:16-21
41. Nahrstedt A, Butterweck V (1997) Biologically active and other chemical constituents of the herb of Hypericum perforatum L. Pharmacopsychiatry 30 (suppl 2):129-134
42. Nathan PJ (1999) The experimental and clinical pharmacology of St. John's Wort (Hypericum perforatum L). Molec Psychiatry 4:333-338
43. Nierenberg AA, Burt T, Matthews J, Weiss AP (1999) Mania associated with St. John's Wort. Biol Psychiatry 46:1707-1708
44. Perovic S, Müller WEG (1995) Pharmacological profile of Hypericum extract: effect on serotonin reuptake by postsynaptic receptors. Arzneimittelforschung 45:1145-1148
45. Philipp M, Kohnen R, Hiller K (1999) Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. Br Med J 19:1534-1539
46. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J (2000) Indinavir concentrations and St. John's Wort. Lancet 355:547-548
47. Porsolt RD, Le Pichon M, Jalfre M (1977) Depression: a new animal model sensitive to antidepressant treatments. Nature 266:730-732
48. Reh C, Laux P, Schenk N (1992) Hypericum-Extrakt bei Depressionen - eine wirksame Alternative. Therapiewoche 42:1576-1581
49. Robinson DS, Rickels K (2000) Concern about clinical drug trials. J Clin Psychopharmacol 20:593-596
50. Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G (2000) Acute heart transplant rejection due to Saint John's Wort. Lancet 355:548-549
51. Schellenberg R, Sauer S, Dimpfel W (1998) Pharmacodynamic effects of two different hypericum extracts in healthy volunteers measured by quantitative EEG. Pharmacopsychiatry 31:44-53
52. Schrader E, Meier B, Brattstrom A (1998) Hypericum treatment of mild-moderate depression in a placebo-controlled study. A prospective, double-blind, randomized, placebo-controlled, multicentre study. Hum Psychopharmacol 13:163-169
53. Schulz V (2000) Psychodynamic and pharmacodynamic effects of drugs: a differentiated evaluation of the efficacy of phytotherapy. Phytomed 7:73-81
54. th edition. Berlin: Springer, pp 474-495
55. Schwabe U, Paffrath D (eds) (1999) Arzneiverordnungsreport 1998. Berlin, Heidelberg: Springer, pp 455-478
56. Sharpley AL, McGavin CL, Whale R, Cowell PI (1998) Antidepressant-like effect of Hypericum perforatum (St. John's Wort) on the sleep polysomnogram. Psychopharmacol 139:286-287
57. Shelton RC, Keller MB, Gelenberg A, Dunner DL, Hirschfeld R, Thase ME, Russell J, Lydiard RB, Crits-Cristoph P, Gallop R, Todd L, Hellerstein D, Goodnick P, Keitner G, Stahl SM, Halbreich U (2001) Effectiveness of St. John's Wort in major depression. A randomized controlled trial. J Am Med Assoc 285:1978-1986
58. Southwell IA, Campbell MH (1991) Hypericin content variation in Hypericum perforatum in Australia. Phytochemistry 30:475-478
59. 2A Receptors. Pharmacopsychiatry 30 (suppl 2):117-124
60. Vandenbogaerde A, Zanoli P, Puia G, Truzzi C, Kamuhabwa A, De Witte P, Merlevede W, Baraldi M (2000) Evidence that total extract of hypericin perforatum affects exploratory behaviour and exerts anxiolytic effects in rats. Pharmacol Biochem Behav 65:627-633
61. Vorbach EU, Arnold KH, Hubner WD (1997) Efficacy and tolerability of St. John's Wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD-10. Pharmacopsychiatry 30 (suppl 2):81-85
62. Whiskey E, Werneke U, Taylor D (2001) A systematic review and meta-analysis of Hypericum perforatum in depression: a comprehensive clinical review. Int Clin Psychopharmacol 16:239-252
63. Woelk H (2000) Comparison of St. John's Wort and imipramine for treating depression: randomised controlled trial. Br Med J 321:536-539
64. st Century (EUR/RC4810). World Health Organization, Geneva
65. Yue Q-Y, Bergquist C, Gerden B (2000) Safety of St. John's Wort (Hypericum perforatum). Lancet 355:576-577